Table 5 Ovary
Author | Cases n | Controlsa/Cohortb | Source population | Exposure definition | Exposure assessment | Drug | RR | 95% CI |
|---|---|---|---|---|---|---|---|---|
Tzonou et al. [47] | 189 | 200a | Hospital based | >2 tablets/week | Personal Interview | NSAIDs (26%) | 0.51 | 0.26–1.02 |
Cramer et al. [28] | 563 | 523a | Population based | >1 tablet/week for >6 months. 1 year lag time. | Personal Interview | Aspirin†(14%) | 0.75 | 0.52–1.10 |
|  |  |  |  |  |  | NSAIDs‡ (7%) | 0.91 | 0.53–1.54 |
Tavani et al. [45] | 749 | 898a | Hospital based | >1 tablet/week for >6 months. (current and/or former) | Personal Interview | Aspirin (6%) | 0.93 | 0.53–1.62 |
Rosenberg[56] | 448 | 4,906a | Hospital based | >3 days/week for >3 months 1.5 years of lag time | Personal Interview | NSAIDs (6%) | 0.8 | 0.5–1.3 |
Rosenberg et al. [42] | 780 | 2,570a | Hospital based | >4 days/week for at least 6 months.1 year lag time | Personal Interview | Aspirin (5%) | 0.8 | 0.5–1.2 |
|  |  |  |  |  |  | NA-NSAIDs (3%) | 0.5 | 0.3–1.0 |
|  |  |  |  |  |  | NSAIDs (8%) | 0.7 | 0.5–1.0 |
Moysich et al. [37] | 547 | 1,094a | Hospital based | >1 day/week for 6 consecutive months | In-hospital Questionnaire | Aspirin (12%) | 1.00 | 0.73–1.39 |
Akhmedkhanov et al. [21] | 68 | 680a | Population based | Ever use of >3 tablet/week for >6 months. 1 year lag time | Mailed Questionnaire | Aspirin (16%) | 0.60 | 0.26–1.38 |
Meier et al. [61] | 483 | 1,877a | Population based | ≥30 prescriptions. 1 year lag time | Automated Database | NSAIDs (5%) | 1.1 | 0.6–1.8 |
Fairfield et al. [50] | 333 | 76,821b | Cohort | >1 tablet/week | Mailed | Aspirin (46%) | 1.00 | 0.80–1.25 |
|  |  |  |  |  |  | NSAIDs (N.R.) | 0.60 | 0.38–0.95 |
-
Prevalence of exposure among controls/cohort; †Over-the-counter only; ‡Prescription only.